# A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis

> **NCT04325776** · PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Bone Metastatic Non-small Cell Lung Cancer

## Interventions

- **DRUG:** AL2846
- **DRUG:** Zoledronic Acid Injection

## Key facts

- **NCT ID:** NCT04325776
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-24
- **Primary completion:** 2021-05
- **Final completion:** 2021-11
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04325776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04325776, "A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04325776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*